ZafgenTM conducted a Phase III study of beloranib, a methionine aminopeptidase 2 inhibitor in PWS patients [25] which showed highly statistically significant improvements in hyperphagia and weight compared to placebo [25]. Here, METAP2 is linked to Prader-Willi syndrome.